What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The evidence from the CheckMate 214 trial indicates that nivolumab with ipilimumab significantly improves overall survival compared to sunitinib, with a median overall survival of 47 months versus 27 months for sunitinib. This demonstrates a clear clinical advantage, supported by robust data from a Phase 3 trial.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for nivolumab with ipilimumab are within the range that NICE considers acceptable for Healthcare resources, suggesting it is marginally cost-effective. The committee noted that the ICERs were towards the higher end of the acceptable range but still defensible.
Is there quality-of-life evidence payers weigh? — Quality of life
While the document does not provide extensive HRQoL data, it indicates that nivolumab with ipilimumab is well tolerated compared to tyrosine kinase inhibitors, which can cause significant adverse effects impacting quality of life. This suggests a moderate improvement in HRQoL, although specific validated tools were not mentioned.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Nivolumab with ipilimumab has a favorable safety profile compared to standard tyrosine kinase inhibitors, which are associated with significant adverse effects. The committee concluded that nivolumab with ipilimumab is well tolerated, indicating a very good safety profile.
Was the drug compared against what payers expect? — Comparator Selection
The treatment was compared against appropriate standard-of-care options, specifically sunitinib and pazopanib, which are considered clinically equivalent. This selection aligns with current clinical practice and guidelines.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population included a broad range of patients with intermediate and poor-risk disease, although there were some limitations regarding the representation of favorable-risk patients. Overall, the population is considered moderately representative of the intended use.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Nivolumab with ipilimumab can be integrated into existing treatment pathways with manageable adjustments, as it is a new option for patients who would otherwise receive tyrosine kinase inhibitors.
Are the wider system costs understood? — Resource Use and Cost Implications
The resource implications are notable but justifiable given the expected benefits. The economic model suggests that the treatment is manageable within the Healthcare budget, although it may require careful planning.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence is derived from a robust Phase 3 RCT (CheckMate 214) with a substantial sample size and low risk of bias. The committee found the evidence to be strong and consistent, supported by additional data from the SACT dataset.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While there are uncertainties regarding long-term outcomes and the impact of treatment crossover, the committee found these to be manageable within the context of the evidence presented. The societal context supports the use of the treatment.
